BR112021021299A2 - Composições e métodos para tratamento de câncer - Google Patents
Composições e métodos para tratamento de câncerInfo
- Publication number
- BR112021021299A2 BR112021021299A2 BR112021021299A BR112021021299A BR112021021299A2 BR 112021021299 A2 BR112021021299 A2 BR 112021021299A2 BR 112021021299 A BR112021021299 A BR 112021021299A BR 112021021299 A BR112021021299 A BR 112021021299A BR 112021021299 A2 BR112021021299 A2 BR 112021021299A2
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- methods
- treating cancer
- therapeutics
- cancer
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 239000003814 drug Substances 0.000 abstract 2
- 230000001413 cellular effect Effects 0.000 abstract 1
- -1 for example Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by targeting or presenting multiple antigens
- A61K2239/29—Multispecific CARs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
omposições e métodos para tratamento de câncer. a presente invenção refere-se a composições, por exemplo, composições compreendendo terapêutico celular e/ou terapêutico de proteína, e métodos de uso de tais composições para tratar câncer são descritos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962839376P | 2019-04-26 | 2019-04-26 | |
PCT/US2020/029967 WO2020219989A1 (en) | 2019-04-26 | 2020-04-24 | Compositions and methods for treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021021299A2 true BR112021021299A2 (pt) | 2021-12-14 |
Family
ID=72941772
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021021299A BR112021021299A2 (pt) | 2019-04-26 | 2020-04-24 | Composições e métodos para tratamento de câncer |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220387487A1 (pt) |
EP (1) | EP3958876A4 (pt) |
JP (1) | JP2022532994A (pt) |
KR (1) | KR20220003045A (pt) |
CN (1) | CN114007626A (pt) |
AU (1) | AU2020262956A1 (pt) |
BR (1) | BR112021021299A2 (pt) |
CA (1) | CA3137962A1 (pt) |
IL (1) | IL287538A (pt) |
MX (1) | MX2021013117A (pt) |
WO (1) | WO2020219989A1 (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024055023A2 (en) * | 2022-09-08 | 2024-03-14 | Virogin Biotech Canada Ltd | Adapter for universal tumor targeting |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2322547A1 (en) * | 2003-06-25 | 2011-05-18 | Crucell Holland B.V. | Myeloid cell-specific lectin |
EP2563816B1 (en) * | 2010-04-27 | 2014-11-12 | National Research Council of Canada | Anti-icam-1 single domain antibody and uses thereof |
US11655452B2 (en) * | 2015-06-25 | 2023-05-23 | Icell Gene Therapeutics Inc. | Chimeric antigen receptors (CARs), compositions and methods of use thereof |
WO2017075537A1 (en) * | 2015-10-30 | 2017-05-04 | Aleta Biotherapeutics Inc. | Compositions and methods for treatment of cancer |
CN108290955A (zh) * | 2015-11-24 | 2018-07-17 | 塞勒兰特治疗公司 | 人源化抗-cll-1抗体 |
EP3655435A1 (en) * | 2017-07-20 | 2020-05-27 | NBE-Therapeutics AG | Multispecific antibody product that binds to different ror1 epitopes |
WO2019118918A1 (en) * | 2017-12-15 | 2019-06-20 | Aleta Biotherapeutics Inc. | Cd19 variants |
WO2020052542A1 (en) * | 2018-09-10 | 2020-03-19 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies against cll1 and constructs thereof |
-
2020
- 2020-04-24 MX MX2021013117A patent/MX2021013117A/es unknown
- 2020-04-24 WO PCT/US2020/029967 patent/WO2020219989A1/en unknown
- 2020-04-24 CA CA3137962A patent/CA3137962A1/en active Pending
- 2020-04-24 KR KR1020217038771A patent/KR20220003045A/ko unknown
- 2020-04-24 AU AU2020262956A patent/AU2020262956A1/en not_active Abandoned
- 2020-04-24 CN CN202080046175.XA patent/CN114007626A/zh active Pending
- 2020-04-24 BR BR112021021299A patent/BR112021021299A2/pt unknown
- 2020-04-24 JP JP2021563350A patent/JP2022532994A/ja active Pending
- 2020-04-24 US US17/605,711 patent/US20220387487A1/en active Pending
- 2020-04-24 EP EP20795219.3A patent/EP3958876A4/en not_active Withdrawn
-
2021
- 2021-10-24 IL IL287538A patent/IL287538A/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3958876A4 (en) | 2023-04-26 |
KR20220003045A (ko) | 2022-01-07 |
CA3137962A1 (en) | 2020-10-29 |
WO2020219989A1 (en) | 2020-10-29 |
CN114007626A (zh) | 2022-02-01 |
EP3958876A1 (en) | 2022-03-02 |
US20220387487A1 (en) | 2022-12-08 |
MX2021013117A (es) | 2022-02-11 |
AU2020262956A1 (en) | 2021-12-16 |
IL287538A (en) | 2021-12-01 |
JP2022532994A (ja) | 2022-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018008326A2 (pt) | composições e métodos para o tratamento de câncer | |
BR112019017403A2 (pt) | composições e métodos para o tratamento de câncer | |
EA201991862A1 (ru) | Композиции и способы, предназначенные для лечения гемоглобинопатий | |
MX2022013526A (es) | Degradadores de proteinas y usos de los mismos. | |
MX2020009366A (es) | Anticuerpos anti-cd73 y usos de los mismos. | |
CR20220240A (es) | Inhibidores de ras | |
CR20220243A (es) | Inhibidores de ras | |
CR20220241A (es) | Inhibidores de ras | |
PH12019501973A1 (en) | Anti-phf-tau antibodies and uses thereof | |
BR112021022504A2 (pt) | Inibidores de autofagia de fenilaminopirimidina amida e métodos de uso dos mesmos | |
EA201891028A1 (ru) | Триспецифические и/или тривалентные связывающие белки для предупреждения или лечения инфекции, вызываемой hiv | |
CA3156451A1 (en) | ANTIBODIES WITH SPECIFICITY FOR NECTIN-4 AND THEIR USES | |
BR112021022576A2 (pt) | Inibidores de autofagia de heteroarilaminopirimidina amida e métodos de uso dos mesmos | |
BR112018068340A2 (pt) | imunoglobulinas de ligação ao tgfss1 e usos destas | |
BR112018070163A2 (pt) | compostos de aminopurina substituída, composições e métodos de tratamento | |
EA201891268A1 (ru) | Соединения, которые можно применять в качестве ингибиторов киназы | |
BR112017016068A2 (pt) | composições para modulação de expressão de c9orf72 | |
EA201891399A1 (ru) | Бипиразолильные производные, пригодные для лечения аутоиммунных заболеваний | |
BR112021025645A2 (pt) | Degradação de proteína alvo de parp14 para uso em terapia | |
BR112021015616A2 (pt) | Ligantes de pseudoquinase tyk2 | |
MX2022002682A (es) | Anticuerpos anti-cd73. | |
MX2019003077A (es) | Anticuerpos novedosos contra el factor xi y sus usos. | |
MX2019000235A (es) | Eliminacion de la cistina mediada por enzimas humanas. | |
BR112022008821A2 (pt) | Ligantes de pseudoquinase tyk2 | |
CL2021001903A1 (es) | Tratamiento de la hepatotoxicidad |